EXEL News and Press, Exelixis Inc. From 10/23/23

2023-10-23 10:44:57 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...

– Cabozantinib compared with placebo reduced the risk of disease progression or death in patients with pancreatic NET and in patients with extra-pancreatic NET – – Exelixis will discuss the results with the U.S. Food and Drug Administration – ...

2023-10-19 08:15:00 ET Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived -- Vertex Pharmaceuticals , Regeneron Pharmaceuticals , an...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT,...

2023-10-02 09:49:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Low-beta stocks allow investors to sleep well at night as the latest developments on interest rate hikes and their effects on the market cause anxiety. Despite things being slightly better than...

2023-09-26 11:47:19 ET More on Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck Exelixis: Long-Term Problem Isn't Shar...

2023-09-20 14:15:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Reserve’s decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on. That...

2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...

2023-09-12 13:05:23 ET More on Exelixis Seeking Alpha’s Quant Rating on Exelixis Historical earnings data for Exelixis Financial information for Exelixis Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade) Exelixis: Posi...

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In April 2023, the U.S....